Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest acquisitions in nearly a decade and its first ...

Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. While Abbott Laboratories saw sales fall in the first ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

Abbott Laboratories' fortunes rose in the second quarter through significantly higher sales of rapid COVID tests compared to last year, while its troubled infant formula business fell, the North ...

CHICAGO (WLS) -- A new COVID19 test that provides results in five minutes is set to roll out soon as Illinois-based Abbott Labs expected to deliver 50,000 tests per-day. President Donald Trump did a ...

About 3 million glucose monitoring sensors were potentially affected by a production error that caused incorrect low glucose readings.

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...

Abbott announced that it initiated a medical device correction for certain glucose sensors in the United States. Internal ...

Abbott Laboratories first quarter profits eclipsed $2.4 billion thanks to a surge in sales of Covid-19 diagnostic tests, the company said April 20, 2022. In this photo, Abbott Chairman of the Board ...